Wei Dong Wang
Founder chez REMEGEN CO., LTD.
Fortune : 43 M $ au 31/03/2024
Profil
Wei Dong Wang is the founder of RemeGen Co., Ltd.
(founded in 2008) and Yantai Rongchang Pharmaceutical Co. Ltd.
(founded in 1993), where he held the title of Chairman.
He is currently the Director at MabPlex International Co., Ltd.
since 2013.
Mr. Wang received his undergraduate degree from Harbin University of Commerce in 1982.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
REMEGEN CO. LTD. CLASS A
2,57% | 28/12/2022 | 4 111 338 ( 2,57% ) | 31 M $ | 31/03/2024 |
REMEGEN CO. LTD. CLASS H
1,89% | 01/10/2023 | 3 584 541 ( 1,89% ) | 12 M $ | 31/03/2024 |
Postes actifs de Wei Dong Wang
| Sociétés | Poste | Début |
|---|---|---|
| REMEGEN CO., LTD. | Founder | 04/07/2008 |
| Yantai Rongchang Pharmaceutical Co. Ltd. | Founder | 01/03/1993 |
MabPlex International Co., Ltd.
 MabPlex International Co., Ltd. Pharmaceuticals: MajorHealth Technology MabPlex International Co., Ltd. engages in the provision of contract development and manufacturing organization (CDMO) services in the biopharmaceutical field. It provides CDMO services for monoclonal antibodies, double antibodies, polyclonal antibodies, fusion proteins, antibody-drug conjugates, recombinant vaccines, recombinant proteins, and other biological drugs; and cell culture medium. The company was founded by Jan Min Fang on June 25, 2013 and is headquartered in Yantai, China. | Director/Board Member | 25/06/2013 |
Formation de Wei Dong Wang
| Harbin University of Commerce | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| REMEGEN CO., LTD. | Health Technology |
| Entreprise privées | 2 |
|---|---|
MabPlex International Co., Ltd.
MabPlex International Co., Ltd. Pharmaceuticals: MajorHealth Technology MabPlex International Co., Ltd. engages in the provision of contract development and manufacturing organization (CDMO) services in the biopharmaceutical field. It provides CDMO services for monoclonal antibodies, double antibodies, polyclonal antibodies, fusion proteins, antibody-drug conjugates, recombinant vaccines, recombinant proteins, and other biological drugs; and cell culture medium. The company was founded by Jan Min Fang on June 25, 2013 and is headquartered in Yantai, China. | Health Technology |
| Yantai Rongchang Pharmaceutical Co. Ltd. |
